Clinical Trials

Phase 2/3 Active not recruiting

992 enrolled

Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

NCT02339571 2026-03-17

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

600 enrolled

Melanoma

NCT06203600 2026-03-17

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

224 enrolled

Adenocarcinoma Of Esophagus

NCT04396860 2026-03-05

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

159 enrolled 17 charts

Sarcoma

Gliosarcoma

NCT07221149 2026-03-04

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

690 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06581406 2026-02-18

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

280 enrolled

Phase 2/3 Not yet recruiting

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT07392892 2026-02-06

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

840 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT04887870 2025-10-10

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

52 enrolled

Advanced or Metastatic Solid Malignancies

NCT06624644 2025-09-10

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

135 enrolled

Phase 2/3 Active not recruiting

Melanoma

NCT03470922 2025-09-09

RELATIVITY-047

714 enrolled 17 charts 1 FDA

Melanoma, Neoplasms

NCT04695977 2025-09-05

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

Phase 2/3 Terminated

20 enrolled 18 charts

Melanoma

NCT05595447 2025-03-12

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

20 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT04901988 2025-02-27

DETECTION

Phase 2/3 Terminated

8 enrolled

Melanoma

NCT04268888 2025-02-26

TACE-3

Phase 2/3 Suspended

522 enrolled

Carcinoma, Hepatocellular

NCT03366272 2025-01-28

NIVEAU

348 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT03092674 2025-01-16

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

MyeloidOther hematologic neoplasm

76 enrolled 16 charts

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02746796 2024-05-03

Study of ONO-4538 in Gastric Cancer

680 enrolled

Stomach Neoplasms

NCT03879122 2022-10-26

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Phase 2/3 Unknown

135 enrolled

Genitourinary

Prostatic Neoplasms

NCT05213312 2022-06-15

Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC

Phase 2/3 Unknown

90 enrolled

Esophageal Squamous Cell Carcinoma

NCT04044651 2020-01-09

Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection

Phase 2/3 Withdrawn